Managed Access Programs are a key pillar of the drug development lifecycle, yet they remain widely misunderstood – both by the people who need them most and those trying to implement them. Part of the reason for this is language. There are many overlapping and inconsistently used terms in this field, which can confuse both the people who might benefit from access programs and those trying to support them. For many patients facing serious or life-threatening illness, diagnosis is only the first hurdle. They can then be told that there are no treatment options available to them. This is where Managed Access Programs can come in – offering not just a potential treatment pathway, but hope. This guide will explain what MAPs are, why they exist, how they work and why they matter, helping point you in the right direction.
What is a Managed Access Program?
Managed Access Programs (often shortened to MAP) are formal pathways that allow patients to access medicines that aren’t approved or available yet in their country, when no suitable alternative treatment exists. They provide an ethical pathway to accelerate access to care for patients with the most to lose. For some they are a last resort. For others they are the only option available. Typically, there are four ways a Managed Access Program will fill the treatment gap:
- A patient isn’t eligible for a clinical trial
- A medicine is still in development or awaiting regulatory approval
- A treatment has been approved elsewhere but isn’t available locally to them
- A medicine is approved but won’t be reimbursed for their specific condition
Patients will almost always be placed on a program at the request of a treating physician, someone who represents either a specific patient or group of patients. That request is then granted under specific pre-defined medical, regulatory, and ethical conditions. The terminology and structure of MAPs varies around the world, but the underlying principle is always the same: to give controlled, responsible access to treatments when there’s no suitable alternative.
It’s all about time
Drug development takes time. Regulatory approval takes time. Reimbursement negotiations often take even longer. And it’s time that many patients just don’t have. Even if your life isn’t threatened, waiting for treatment can take a huge toll physically and emotionally. Managed Access Programs exist to bridge that gap – shortening the time between scientific progress and real-world patient access. As well as providing potentially life-saving or life-extending treatment they can offer hope when standard care options have been exhausted, and make sure treatment doesn’t abruptly stop when the clinical trial does. All overseen with a carefully structured and ethical process. It’s not just a lifeline for patients. MAPs can give families and caregivers more time, stability, and options – even when those options are limited.
Managed Access vs Clinical Trials
One of the most common misunderstandings is that access programs are simply another kind of clinical trial. They are not. Clinical trials exist to answer scientific questions and generate data. Managed Access Programs exist to treat patients. There is no randomisation, no placebo, and no study protocol driving treatment decisions. Physicians make decisions based on their patient’s clinical need, with the focus on safety, oversight, and appropriate use – not data collection.
The language problem: why access can feel so confusing
One reason access programs are so poorly understood is that they go by so many different names. Depending on the country, you may find them described as:
- Early Access Programs
- Compassionate Use
- Expanded Access
- Named Patient Programs
- Post-Trial Access
These terms often overlap, and in some cases, the same term will mean entirely different things in different regions. There is no single global framework, and very little harmonisation. As a result, patients may struggle to understand what options exist, physicians aren’t sure what pathways exist, and smaller biotechs may not even realise access programs are an option for their drugs. Properly understanding access isn’t about memorising definitions – it’s about understanding local regulatory interpretation and practice. But it can help to know what these common labels are usually taken to mean: so we’ve outlined a brief explanation of each.
1. Early Access and Compassionate Use Programs
Early Access or Compassionate Use Programs typically allow groups of patients to access a treatment before it has full regulatory approval. In countries where these programs exist they are usually highly structured and governed by national health authorities, with strict safety reporting and oversight. They will usually have clear eligibility criteria and in some cases are even reimbursed by the national health system. In this way they can become a critical part of the healthcare system – particularly for oncology and rare diseases. However, Early Access or Compassionate Use Programs don’t formally exist at all in some regions. So those patients have no alternative other than waiting for standard regulatory and commercial pathways to reach them.
2. Named Patient Programs
Named Patient Programs (NPPs) are one of the most widely used access mechanisms in the world, allowing an individual treating physician to apply for treatment on behalf of an individual patient. If approved, it can allow them to access unlicensed or unavailable medicines, sometimes free of charge or chargeable, depending on local regulations. In countries where there are no early access frameworks, NPPs are often the only viable route for patients to access innovative therapies and – although they may appear ‘ad hoc’ from the outside – well-run NPPs are carefully managed to ensure patient safety, regulatory compliance, and traceable supply.
3. Post-Trial Access
Continuity of care matters and Post-Trial Access ensures that patients who have benefited from a clinical trial can carry on receiving treatment once the study ends. From an ethical standpoint, this is increasingly seen as essential. Discontinuing a therapy that is clearly benefiting a patient simply because a trial has finished raises serious concerns. Post-Trial Access programs can help to stabilise care in the short term while more long-term approval or reimbursement avenues are pursued.
An inconsistent picture
Managed Access Programs are far from globally consistent. While some countries have clear regulations, guidance, and approval processes for access programs that are widely understood by hospitals and physicians – including effective reimbursement mechanisms – in others it can be a very different picture. In some countries there may be little or no formal guidance, leaving access reliant on local interpretation and precedent through fragmented or poorly understood processes. This variability is one of the biggest challenges in global access – and one of the reasons why experience and local knowledge can matter so much to an individual patient’s experience. Because those processes and frameworks are absolutely critical. It’s not simply about supplying medicines. Managed Access must be actively ‘managed’. To be safe and ethical a program requires:
- Country-specific regulatory assessment
- Clear patient eligibility criteria
- Oversight of informed consent
- Safety reporting and pharmacovigilance
- Importation and customs management
- Secure, traceable supply chains
- Transparent communication with physicians and sites
Without these managerial guardrails, the process can become fragmented, risky, and inconsistent – and potentially compromise both patient safety and company compliance. But it’s worth the work to put them in place. Because access matters.
Why access matters
Access matters for everyone involved. Managed Access Programs give physicians a legitimate pathway to support patients responsibly when other options no longer exist. They give pharmaceutical and biotech companies a way to support patients ethically, manage risk, and maintain visibility and control – instead of simply leaving access to chance. And most importantly they can give patients and families more time, more options, more dignity and – above all – hope. The pathways they create may be complicated, but MAPs shine a light on a fundamental truth about medical innovation. Namely that it only matters if patients can access it.
